Annual Total Long Term Liabilities
$1.60 B
+$106.30 M+7.11%
31 December 2023
Summary:
Vertex Pharmaceuticals Incorporated annual total long term liabilities is currently $1.60 billion, with the most recent change of +$106.30 million (+7.11%) on 31 December 2023. During the last 3 years, it has risen by +$414.90 million (+34.94%). VRTX annual total long term liabilities is now at all-time high.VRTX Long Term Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Long Term Liabilities
$2.64 B
+$826.00 M+45.63%
30 September 2024
Summary:
Vertex Pharmaceuticals Incorporated quarterly total long term liabilities is currently $2.64 billion, with the most recent change of +$826.00 million (+45.63%) on 30 September 2024. Over the past year, it has increased by +$1.02 billion (+63.33%). VRTX quarterly long term liabilities is now at all-time high.VRTX Quarterly Long Term Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
VRTX Long Term Liabilities Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +7.1% | +63.3% |
| 3 y3 years | +34.9% | +124.6% |
| 5 y5 years | +132.1% | +202.2% |
VRTX Long Term Liabilities High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | +34.9% | at high | +146.9% |
| 5 y | 5 years | at high | +132.1% | at high | +202.2% |
| alltime | all time | at high | >+9999.0% | at high | >+9999.0% |
Vertex Pharmaceuticals Incorporated Long Term Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $2.64 B(+45.6%) |
| June 2024 | - | $1.81 B(+14.9%) |
| Mar 2024 | - | $1.57 B(-1.7%) |
| Dec 2023 | $1.60 B(+7.1%) | $1.60 B(-0.7%) |
| Sept 2023 | - | $1.61 B(+5.7%) |
| June 2023 | - | $1.53 B(+0.7%) |
| Mar 2023 | - | $1.52 B(+1.3%) |
| Dec 2022 | $1.50 B(+25.7%) | $1.50 B(+40.1%) |
| Sept 2022 | - | $1.07 B(-2.3%) |
| June 2022 | - | $1.09 B(-6.5%) |
| Mar 2022 | - | $1.17 B(-1.8%) |
| Dec 2021 | $1.19 B(+0.3%) | $1.19 B(+1.4%) |
| Sept 2021 | - | $1.17 B(-1.3%) |
| June 2021 | - | $1.19 B(-0.2%) |
| Mar 2021 | - | $1.19 B(+0.3%) |
| Dec 2020 | $1.19 B(+32.2%) | $1.19 B(+2.0%) |
| Sept 2020 | - | $1.16 B(+29.6%) |
| June 2020 | - | $898.49 M(+0.6%) |
| Mar 2020 | - | $892.80 M(-0.6%) |
| Dec 2019 | $898.39 M(+30.1%) | $898.39 M(+3.0%) |
| Sept 2019 | - | $872.26 M(+23.9%) |
| June 2019 | - | $704.29 M(-1.3%) |
| Mar 2019 | - | $713.33 M(+3.3%) |
| Dec 2018 | $690.40 M(-0.9%) | $690.40 M(-0.5%) |
| Sept 2018 | - | $693.85 M(+0.1%) |
| June 2018 | - | $693.20 M(-0.2%) |
| Mar 2018 | - | $694.84 M(-0.2%) |
| Dec 2017 | $696.45 M(-9.1%) | $696.45 M(+1.8%) |
| Sept 2017 | - | $684.34 M(-13.7%) |
| June 2017 | - | $792.96 M(+2.4%) |
| Mar 2017 | - | $774.11 M(+1.1%) |
| Dec 2016 | $766.06 M(-14.8%) | $766.06 M(+12.9%) |
| Sept 2016 | - | $678.46 M(-10.4%) |
| June 2016 | - | $757.28 M(-7.6%) |
| Mar 2016 | - | $819.67 M(-8.8%) |
| Dec 2015 | $898.79 M(+3.3%) | $898.79 M(-8.5%) |
| Sept 2015 | - | $982.30 M(+3.2%) |
| June 2015 | - | $952.03 M(+10.0%) |
| Mar 2015 | - | $865.85 M(-0.5%) |
| Dec 2014 | $870.24 M(+54.1%) | $870.24 M(-0.9%) |
| Sept 2014 | - | $878.00 M(+50.7%) |
| June 2014 | - | $582.58 M(-1.7%) |
| Mar 2014 | - | $592.73 M(+4.9%) |
| Dec 2013 | $564.81 M(-50.1%) | $564.81 M(-22.2%) |
| Sept 2013 | - | $726.19 M(+4.8%) |
| June 2013 | - | $693.23 M(-33.8%) |
| Mar 2013 | - | $1.05 B(-7.4%) |
| Dec 2012 | $1.13 B(+28.0%) | $1.13 B(+8.0%) |
| Sept 2012 | - | $1.05 B(+6.7%) |
| June 2012 | - | $981.54 M(+11.1%) |
| Mar 2012 | - | $883.45 M(-0.0%) |
| Dec 2011 | $883.46 M(+18.3%) | $883.46 M(+8.8%) |
| Sept 2011 | - | $812.20 M(-2.7%) |
| June 2011 | - | $834.95 M(+14.3%) |
| Mar 2011 | - | $730.62 M(-2.2%) |
| Dec 2010 | $746.69 M(+30.0%) | $746.69 M(-19.5%) |
| Sept 2010 | - | $927.17 M(+73.4%) |
| June 2010 | - | $534.69 M(-5.9%) |
| Mar 2010 | - | $568.15 M(-1.1%) |
| Dec 2009 | $574.26 M(+9.4%) | $574.26 M(-21.7%) |
| Sept 2009 | - | $733.38 M(+39.1%) |
| June 2009 | - | $527.14 M(-22.4%) |
| Mar 2009 | - | $679.73 M(+29.5%) |
| Dec 2008 | $525.04 M(+301.1%) | $525.04 M(-2.3%) |
| Sept 2008 | - | $537.20 M(-2.0%) |
| June 2008 | - | $547.99 M(+33.0%) |
| Mar 2008 | - | $411.93 M(+214.7%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2007 | $130.90 M(-20.5%) | $130.90 M(-4.7%) |
| Sept 2007 | - | $137.41 M(-4.3%) |
| June 2007 | - | $143.58 M(-9.8%) |
| Mar 2007 | - | $159.21 M(-3.3%) |
| Dec 2006 | $164.63 M(-21.4%) | $164.63 M(-29.3%) |
| Sept 2006 | - | $232.89 M(-31.9%) |
| June 2006 | - | $341.75 M(+63.1%) |
| Mar 2006 | - | $209.50 M(-0.0%) |
| Dec 2005 | $209.58 M(-41.2%) | $209.58 M(-29.1%) |
| Sept 2005 | - | $295.45 M(-12.1%) |
| June 2005 | - | $335.96 M(-2.5%) |
| Mar 2005 | - | $344.55 M(-3.3%) |
| Dec 2004 | $356.27 M(-9.2%) | $356.27 M(-2.6%) |
| Sept 2004 | - | $365.60 M(-2.8%) |
| June 2004 | - | $376.31 M(-3.8%) |
| Mar 2004 | - | $391.25 M(-0.3%) |
| Dec 2003 | $392.50 M(+5.4%) | $392.50 M(+0.2%) |
| Sept 2003 | - | $391.57 M(+1.1%) |
| June 2003 | - | $387.42 M(+1.0%) |
| Mar 2003 | - | $383.75 M(+3.0%) |
| Dec 2002 | $372.54 M(+4.0%) | $372.54 M(+2.3%) |
| Sept 2002 | - | $364.07 M(+0.7%) |
| June 2002 | - | $361.51 M(+0.5%) |
| Mar 2002 | - | $359.85 M(+0.5%) |
| Dec 2001 | $358.23 M(+0.3%) | $358.23 M(+1.1%) |
| Sept 2001 | - | $354.19 M(+2.2%) |
| June 2001 | - | $346.63 M(-0.1%) |
| Mar 2001 | - | $346.97 M(-2.9%) |
| Dec 2000 | $357.27 M(+7512.8%) | $357.27 M(+2.6%) |
| Sept 2000 | - | $348.12 M(+94.9%) |
| June 2000 | - | $178.62 M(-0.3%) |
| Mar 2000 | - | $179.16 M(+3717.5%) |
| Dec 1999 | $4.69 M(-33.0%) | $4.69 M(-9.8%) |
| Sept 1999 | - | $5.20 M(-10.3%) |
| June 1999 | - | $5.80 M(-9.4%) |
| Mar 1999 | - | $6.40 M(-8.6%) |
| Dec 1998 | $7.00 M(+18.6%) | $7.00 M(-7.9%) |
| Sept 1998 | - | $7.60 M(+10.1%) |
| June 1998 | - | $6.90 M(+11.3%) |
| Mar 1998 | - | $6.20 M(+5.1%) |
| Dec 1997 | $5.90 M(+5.4%) | $5.90 M(+9.3%) |
| Sept 1997 | - | $5.40 M(0.0%) |
| June 1997 | - | $5.40 M(+1.9%) |
| Mar 1997 | - | $5.30 M(-5.4%) |
| Dec 1996 | $5.60 M(+14.3%) | $5.60 M(+27.3%) |
| Sept 1996 | - | $4.40 M(-2.2%) |
| June 1996 | - | $4.50 M(+2.3%) |
| Mar 1996 | - | $4.40 M(-10.2%) |
| Dec 1995 | $4.90 M(+4.3%) | $4.90 M(0.0%) |
| Sept 1995 | - | $4.90 M(-2.0%) |
| June 1995 | - | $5.00 M(0.0%) |
| Mar 1995 | - | $5.00 M(+6.4%) |
| Dec 1994 | $4.70 M(+11.9%) | $4.70 M(+2.2%) |
| Sept 1994 | - | $4.60 M(+4.5%) |
| June 1994 | - | $4.40 M(+15.8%) |
| Mar 1994 | - | $3.80 M(-9.5%) |
| Dec 1993 | $4.20 M(+31.3%) | $4.20 M(+5.0%) |
| Sept 1993 | - | $4.00 M(+5.3%) |
| June 1993 | - | $3.80 M(+11.8%) |
| Mar 1993 | - | $3.40 M(+6.3%) |
| Dec 1992 | $3.20 M(+45.5%) | $3.20 M(0.0%) |
| Sept 1992 | - | $3.20 M(+6.7%) |
| June 1992 | - | $3.00 M(+30.4%) |
| Mar 1992 | - | $2.30 M(+4.5%) |
| Dec 1991 | $2.20 M(-8.3%) | $2.20 M(-4.3%) |
| Sept 1991 | - | $2.30 M(-8.0%) |
| June 1991 | - | $2.50 M(+4.2%) |
| Dec 1990 | $2.40 M | $2.40 M |
FAQ
- What is Vertex Pharmaceuticals Incorporated annual total long term liabilities?
- What is the all time high annual total long term liabilities for Vertex Pharmaceuticals Incorporated?
- What is Vertex Pharmaceuticals Incorporated annual total long term liabilities year-on-year change?
- What is Vertex Pharmaceuticals Incorporated quarterly total long term liabilities?
- What is the all time high quarterly long term liabilities for Vertex Pharmaceuticals Incorporated?
- What is Vertex Pharmaceuticals Incorporated quarterly long term liabilities year-on-year change?
What is Vertex Pharmaceuticals Incorporated annual total long term liabilities?
The current annual total long term liabilities of VRTX is $1.60 B
What is the all time high annual total long term liabilities for Vertex Pharmaceuticals Incorporated?
Vertex Pharmaceuticals Incorporated all-time high annual total long term liabilities is $1.60 B
What is Vertex Pharmaceuticals Incorporated annual total long term liabilities year-on-year change?
Over the past year, VRTX annual total long term liabilities has changed by +$106.30 M (+7.11%)
What is Vertex Pharmaceuticals Incorporated quarterly total long term liabilities?
The current quarterly long term liabilities of VRTX is $2.64 B
What is the all time high quarterly long term liabilities for Vertex Pharmaceuticals Incorporated?
Vertex Pharmaceuticals Incorporated all-time high quarterly total long term liabilities is $2.64 B
What is Vertex Pharmaceuticals Incorporated quarterly long term liabilities year-on-year change?
Over the past year, VRTX quarterly total long term liabilities has changed by +$1.02 B (+63.33%)